Best deals to access real time data! |
|
Ultimate Trader (Monthly)
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
Big Cap Pro
Monthly Subscription
for only
|
|
VAT not included
|
|
After Hours Last Trade |
Last $ 15.17 ◊ 0.00 (0.00%) | |
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Halozyme Therapeutics Incorporated | HALO | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | High Price | Low Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| -0.19 | -1.24% | 15.17 | 15.45 | 15.14 | 15.38 | 15.36 | 18:00:23 |
| Bid Price | Ask Price | Spread | Spread % | News | |
|---|---|---|---|---|---|
| 14.00 | 17.71 | 3.71 | 20.95% | - | - |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 6,606 | 744,440 | $ 15.30 | $ 11,392,880 | 733,234 | 13.24 - 17.85 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 16:15:03 | formt | 241 | $ 15.17 | USD |
Halozyme Therapeutics Financials
| Market Cap | Shares in Issue | Profit/Loss | Earnings Per Share (EPS) | PE Ratio | Float |
|---|---|---|---|---|---|
| $ 2.22B | 146.31M | $ -80.33M | -0.55 | -152.72 | 135.27M |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | - |
Halozyme Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical HALO Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 15.88 | 16.06 | 15.14 | 15.47 | 531,119 | -0.71 | -4.47% |
| 1 Month | 15.81 | 16.19 | 15.07 | 15.59 | 678,887 | -0.64 | -4.05% |
| 3 Months | 17.01 | 17.85 | 15.07 | 16.12 | 730,708 | -1.84 | -10.82% |
| 6 Months | 16.09 | 17.85 | 14.65 | 16.22 | 772,863 | -0.92 | -5.72% |
| 1 Year | 15.40 | 17.85 | 13.24 | 16.07 | 772,990 | -0.23 | -1.49% |
| 3 Years | 9.49 | 21.48 | 8.18 | 15.51 | 1,048,435 | 5.68 | 59.85% |
| 5 Years | 9.05 | 25.25 | 6.96 | 14.43 | 1,188,132 | 6.12 | 67.62% |
Halozyme Therapeutics Description
| Halozyme Therapeutics is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme utilizes a strategy that focuses on developing its own proprietary products in therapeutic areas with significant unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally. |
